2 results
Approved WMOCompleted
The objectives of this study are to assess the efficacy, safety, and tolerability of a once daily oral dose of laquinimod (0.6 or 1.5 mg) compared to placebo in PPMS patients.
Approved WMOPending
To assess the efficacy of inhaled RVT-1601 in comparison with placebo following 12 weeks of treatment